Biocon Share Price
- Advice
- Hold
Start SIP in Biocon
Start SIPBiocon Performance
Day Range
- Low 375
- High 394
52 Week Range
- Low 218
- High 395
- Open Price389
- Previous Close385
- Volume8824201
Biocon F&O
Biocon Investment Rating
-
Master Rating:
-
Biocon (Nse) has an operating revenue of Rs. 14,766.00 Cr. on a trailing 12-month basis. An annual revenue growth of 35% is outstanding, Pre-tax margin of 11% is healthy, ROE of 5% is fair but needs improvement. The company has a debt to equity of 65%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 28% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 64 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 511 | 533 | 563 | 519 | 513 | 507 |
| Operating Expenses Qtr Cr | 466 | 480 | 492 | 452 | 441 | 551 |
| Operating Profit Qtr Cr | 45 | 52 | 71 | 67 | 72 | -44 |
| Depreciation Qtr Cr | 31 | 30 | 31 | 31 | 30 | 29 |
| Interest Qtr Cr | 55 | 40 | 56 | 55 | 48 | 48 |
| Tax Qtr Cr | 0 | 8 | 9 | 11 | 3 | -15 |
| Net Profit Qtr Cr | 1 | 14 | 24 | 35 | 47 | 1,811 |
Biocon Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 14
- Bearish Moving Average
- ___
- 2
- 20 Day
- ₹366.62
- 50 Day
- ₹354.19
- 100 Day
- ₹336.84
- 200 Day
- ₹312.85
- 20 Day
- ₹363.01
- 50 Day
- ₹355.65
- 100 Day
- ₹336.80
- 200 Day
- ₹300.77
Biocon Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 388.68 |
| Second Resistance | 400.77 |
| Third Resistance | 407.68 |
| RSI | 59.37 |
| MFI | 68.56 |
| MACD Single Line | 6.99 |
| MACD | 9.11 |
| Support | |
|---|---|
| First Support | 369.68 |
| Second Support | 362.77 |
| Third Supoort | 350.68 |
Biocon Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 9,125,398 | 288,636,339 | 31.63 |
| Week | 8,995,644 | 367,292,128 | 40.83 |
| 1 Month | 5,921,785 | 221,356,336 | 37.38 |
| 6 Month | 7,428,843 | 284,078,946 | 38.24 |
Biocon Result Highlights
Biocon Synopsis
NSE-Medical-Biomed/Biotech
Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 2127.30 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2024. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.| Market Cap | 45,215 |
| Sales | 2,125 |
| Shares in Float | 46.82 |
| No of funds | 273 |
| Yield | 0.13 |
| Book Value | 4.14 |
| U/D Vol ratio | 1.2 |
| LTDebt / Equity | 19 |
| Alpha | -0.01 |
| Beta | 1.27 |
Biocon Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
|---|---|---|---|---|
| Promoters | 60.64% | 60.64% | 60.64% | 60.64% |
| Mutual Funds | 8.69% | 8.57% | 9.31% | 8.26% |
| Insurance Companies | 5.51% | 5.01% | 5.12% | 5.76% |
| Foreign Portfolio Investors | 5.9% | 5.63% | 6.55% | 7.97% |
| Financial Institutions/ Banks | 0.02% | 0.01% | ||
| Individual Investors | 14.64% | 15.53% | 14.47% | 13.61% |
| Others | 4.6% | 4.61% | 3.91% | 3.76% |
Biocon Management
| Name | Designation |
|---|---|
| Ms. Kiran Mazumdar Shaw | Executive Chairperson |
| Mr. Siddharth Mittal | Managing Director & CEO |
| Prof. Ravi Rasendra Mazumdar | Non Exe.Non Ind.Director |
| Mr. Eric Vivek Mazumdar | Non Exe.Non Ind.Director |
| Mr. Meleveetil Damodaran | Independent Director |
| Mr. Bobby Kanubhai Parikh | Independent Director |
| Mr. Naina Lal Kidwai | Independent Director |
| Ms. Rekha Mehrotra Menon | Independent Director |
| Mr. Nicholas Robert Haggar | Independent Director |
| Mr. Atul Dhawan | Independent Director |
Biocon Forecast
Price Estimates
Biocon Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-08 | Quarterly Results | |
| 2024-05-16 | Audited Results & Final Dividend | |
| 2024-02-08 | Quarterly Results | |
| 2023-11-10 | Quarterly Results | |
| 2023-08-10 | Quarterly Results |
| Date | Purpose | Remarks |
|---|---|---|
| 2024-07-05 | FINAL | Rs.0.50 per share(10%)Final Dividend |
| 2023-07-07 | FINAL | Rs.1.50 per share(30%)Final Dividend |
| 2022-07-01 | FINAL | Rs.0.50 per share(10%)Final Dividend |
About Biocon
Biocon FAQs
What is Share Price of Biocon ?
Biocon share price is ₹376 As on 13 September, 2024 | 06:27
What is the Market Cap of Biocon ?
The Market Cap of Biocon is ₹45214.6 Cr As on 13 September, 2024 | 06:27
What is the P/E ratio of Biocon ?
The P/E ratio of Biocon is 28.6 As on 13 September, 2024 | 06:27
What is the PB ratio of Biocon ?
The PB ratio of Biocon is 1.8 As on 13 September, 2024 | 06:27
Is it a good time to invest in Biocon Limited?
Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.
How many times has Biocon Limited given dividends since 2004?
Biocon Ltd. has declared 17 dividends since July 1, 2004.
What is the stock price CAGR of Biocon Limited?
The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.
What is the debt-to-equity ratio of Biocon Limited?
The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.
What is the ROE of the Biocon Limited?
The ROE of Biocon Limited is 9% which is fair but needs improvement.
Who is the Managing Director of Biocon Limited?
Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.
Is Biocon a good stock to buy?
According to the record analysis of moneyworks4me, Biocom limited is an average quality company.